Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edivoxetine

Next Previous
Drug Profile

Edivoxetine

Alternative Names: EDP-125; LY-2216684

Latest Information Update: 02 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eddingpharm; Eli Lilly and Company
  • Class Antidepressants; Cyclic ethers; Fluorobenzenes; Morpholines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Attention-deficit hyperactivity disorder
  • Discontinued Major depressive disorder

Most Recent Events

  • 02 Feb 2026 No development reported - Phase-III for Attention-deficit hyperactivity disorder (In adolescents, In children) in China (PO) (Eddingpharm Pipeline, February 2026)
  • 27 Jun 2023 Eddingpharm plans to submit NDA to the National Medical Products Administration (NMPA) for Attention deficit hyperactivity disorder (ADHD) in China in the second half of 2023 (Eddingpharm pipeline, June 2023)
  • 22 Dec 2022 Eddingpharm completes a phase-III trial in Attention-deficit hyperactivity disorder (In children, In adolescents) in China (PO)(CTR20211990) (Eddingpharm pipeline, June 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top